Tags

Type your tag names separated by a space and hit enter

Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine.
Vaccine. 2005 Jun 10; 23(30):3902-7.V

Abstract

To determine the minimum vaccine potency per intradermal dose required to elicit an adequate immune response using the Thai Red Cross (TRC) regimen (2-2-2-0-1-1), healthy volunteers received 0.1 mL volumes of PCECV containing decreasing amounts of antigen. Subjects also received HRIG to evaluate potential interference with antibody production. Results indicated that when each 0.1 mL intradermal dose of PCECV contained antigen corresponding to 0.32 IU per intramuscular dose, every subject had titers above 0.5 IU/mL by day 14. These results confirm that the current World Health Organization (WHO) recommendations for vaccine potency (2.5 IU per intramuscular dose) are sufficient for use in the Thai Red Cross intradermal regimen.

Authors+Show Affiliations

Department of Infectious Diseases, University Hospital, Hradec Kralove, Czech Republic.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15917111

Citation

Beran, Jiri, et al. "Potency Requirements of Rabies Vaccines Administered Intradermally Using the Thai Red Cross Regimen: Investigation of the Immunogenicity of Serially Diluted Purified Chick Embryo Cell Rabies Vaccine." Vaccine, vol. 23, no. 30, 2005, pp. 3902-7.
Beran J, Honegr K, Banzhoff A, et al. Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. Vaccine. 2005;23(30):3902-7.
Beran, J., Honegr, K., Banzhoff, A., & Malerczyk, C. (2005). Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. Vaccine, 23(30), 3902-7.
Beran J, et al. Potency Requirements of Rabies Vaccines Administered Intradermally Using the Thai Red Cross Regimen: Investigation of the Immunogenicity of Serially Diluted Purified Chick Embryo Cell Rabies Vaccine. Vaccine. 2005 Jun 10;23(30):3902-7. PubMed PMID: 15917111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. AU - Beran,Jiri, AU - Honegr,Karel, AU - Banzhoff,Angelika, AU - Malerczyk,Claudius, Y1 - 2005/04/06/ PY - 2005/02/14/received PY - 2005/03/11/revised PY - 2005/03/23/accepted PY - 2005/5/27/pubmed PY - 2005/7/28/medline PY - 2005/5/27/entrez SP - 3902 EP - 7 JF - Vaccine JO - Vaccine VL - 23 IS - 30 N2 - To determine the minimum vaccine potency per intradermal dose required to elicit an adequate immune response using the Thai Red Cross (TRC) regimen (2-2-2-0-1-1), healthy volunteers received 0.1 mL volumes of PCECV containing decreasing amounts of antigen. Subjects also received HRIG to evaluate potential interference with antibody production. Results indicated that when each 0.1 mL intradermal dose of PCECV contained antigen corresponding to 0.32 IU per intramuscular dose, every subject had titers above 0.5 IU/mL by day 14. These results confirm that the current World Health Organization (WHO) recommendations for vaccine potency (2.5 IU per intramuscular dose) are sufficient for use in the Thai Red Cross intradermal regimen. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/15917111/Potency_requirements_of_rabies_vaccines_administered_intradermally_using_the_Thai_Red_Cross_regimen:_investigation_of_the_immunogenicity_of_serially_diluted_purified_chick_embryo_cell_rabies_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(05)00362-2 DB - PRIME DP - Unbound Medicine ER -